Antimicrobial resistance

Accelerate Diagnostics Announces CE Mark and Availability in Europe of Fast Antimicrobial Susceptibility Test for Use with Existing ID Systems

Retrieved on: 
Tuesday, August 3, 2021
Articles, Antimicrobial resistance, Evolutionary biology, Pharmaceuticals policy, Veterinary medicine, Life sciences

This is an important new option for the Company's existing Accelerate PhenoTest BC kit, which already had an ID/AST configuration that is a fully integrated solution for labs needing both fast identification and fast AST.

Key Points: 
  • This is an important new option for the Company's existing Accelerate PhenoTest BC kit, which already had an ID/AST configuration that is a fully integrated solution for labs needing both fast identification and fast AST.
  • The Accelerate Pheno system has been shown to deliver improvements in clinical outcomes including time to results, time to optimal therapy, duration of therapy and hospital length of stay.
  • Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis.
  • The "ACCELERATE DIAGNOSTICS" and "ACCELERATE PHENO" and "ACCELERATE PHENOTEST" and diamond shaped logos and marks are trademarks or registered trademarks of Accelerate Diagnostics, Inc.
    For more information about the company, its products and technology, or recent publications, visit axdx.com .

Armata Pharmaceuticals Announces Chief Executive Officer Transition

Retrieved on: 
Monday, August 2, 2021
Articles, Life sciences, Bacteriophage, Biology, Antimicrobial resistance, Armata

MARINA DEL REY, Calif., Aug. 2, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata," "us," "our," or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that its current Chief Executive Officer, Todd R. Patrick, is retiring from day-to-day active management of the Company, effective today. The Company's current President and Chief Development Officer, Brian Varnum, Ph.D., has been appointed Chief Executive Officer. Mr. Patrick will continue to serve on Armata's Board of Directors and has agreed to act as a special advisor to the Company through at least 2022.

Key Points: 
  • MARINA DEL REY, Calif., Aug. 2, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata," "us," "our," or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that its current Chief Executive Officer, Todd R. Patrick, is retiring from day-to-day active management of the Company, effective today.
  • The Company's current President and Chief Development Officer, Brian Varnum, Ph.D., has been appointed Chief Executive Officer.
  • "At the same time, we are fortunate to have someone with Brian's extensive drug development experience on the team and I would like to congratulate him on his well-deserved elevation to the Chief Executive Officer role."
  • Armata is committed to advancing its bacteriophage-based technology with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.

Entasis Therapeutics and Zai Lab Complete Patient Enrollment in the ATTACK Phase 3 Registrational Clinical Trial of Sulbactam-Durlobactam

Retrieved on: 
Tuesday, July 27, 2021
Health, Articles, Moraxellaceae, Carbapenem, Healthcare-associated infections, Acinetobacter, Antimicrobial resistance, Antibiotic, ESKAPE

WALTHAM, Mass. and SHANGHAI, China and SAN FRANCISCO, July 27, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, and Zai Lab Limited (NASDAQ:ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, announced today that patient enrollment in the ATTACK Phase 3 registrational clinical trial of sulbactam-durlobactam (SUL-DUR) is now complete, with top-line data readout anticipated early in the fourth quarter of 2021.

Key Points: 
  • To our knowledge, ATTACK is the largest antibiotic-resistant, pathogen-specific registrational trial to be conducted globally and the first to focus specifically on carbapenem-resistant Acinetobacter infections.
  • Harald Reinhart, M.D., Chief Medical Officer for Autoimmune and Infectious Diseases at Zai Lab, stated, Infections caused by carbapenem-resistant Acinetobacter spp.
  • ATTACK is a Phase 3 registrational trial that will evaluate the safety and efficacy of SUL-DUR in patients with confirmed carbapenem-resistant Acinetobacter infections.
  • ATTACK is a global Phase 3 registration trial that enrolled patients at clinical sites from 17 countries.

Canadian fast-food companies failing when it comes to chicken welfare says new global report

Retrieved on: 
Tuesday, July 27, 2021
Restaurant chains, Restaurants, Fast-food restaurants, Pharmaceuticals policy, Veterinary medicine, Evolutionary biology, Antimicrobial resistance, Domino's Pizza, Starbucks, Subway, Chicken as food, Super Bug

Intensive farming methods also often rely on routine antibiotic use as a quick fix solution to keep stressed and sick animals alive.

Key Points: 
  • Intensive farming methods also often rely on routine antibiotic use as a quick fix solution to keep stressed and sick animals alive.
  • This over-use of antibiotics is fueling the deadly superbug crisis that kills over 700,000 people globally a year.
  • The latestreport called" Thepeckingorder 2021" ranksthesefast food restaurantsgloballyon how they are performing on their commitment, ambition, and transparency on chicken welfare in their supply chains.
  • Three companies received zero points for their Canadian policies - Starbucks, Subway and Domino's, although they have signed up to the BCC in other markets.

Statement from the Minister of Health on the Antimicrobial Resistance (AMR) Network Report

Retrieved on: 
Tuesday, July 20, 2021
Articles, Health sciences, Health, Health Canada, Evolutionary biology, Pharmaceuticals policy, Veterinary medicine, Antimicrobial resistance, Public Health Agency of Canada, Minister of Health, AMR

OTTAWA, ON, July 20, 2021 /CNW/ - The Honourable Patty Hajdu, Minister of Health, today issued the following statement.

Key Points: 
  • OTTAWA, ON, July 20, 2021 /CNW/ - The Honourable Patty Hajdu, Minister of Health, today issued the following statement.
  • The antimicrobial (AMR) Network recently released its final report, Strengthening Governance of the Antimicrobial Resistance Response Across One Health in Canada.
  • The AMR Network was funded by the Public Health Agency of Canada (PHAC) to explore governance models that unite diverse stakeholders in this important work.
  • Antimicrobial resistance is a complex global challenge, and this report will help all parties move toward a One Health approach to tackle this universal issue.

CHOP Researchers Establish Novel Approach for Developing New Antibiotics

Retrieved on: 
Monday, July 19, 2021
Health sciences, Medical specialties, Medicine, Antibiotics, Bacteria, Bacteriology, Drug resistance, Pharmaceuticals policy, Production of antibiotics, Antimicrobial resistance

PHILADELPHIA, July 19, 2021 /PRNewswire/ --Researchers at Children's Hospital of Philadelphia (CHOP) have developed a novel method for producing new antibiotics to combat resistant bacteria.

Key Points: 
  • PHILADELPHIA, July 19, 2021 /PRNewswire/ --Researchers at Children's Hospital of Philadelphia (CHOP) have developed a novel method for producing new antibiotics to combat resistant bacteria.
  • Through an approach that would target bacteria with an antibiotic that is masked by a prodrug, which the bacteria would themselves remove, the researchers identified a method that would allow for development of new, effective antibiotics that could overcome issues of resistance.
  • "Using structure-guided design, we have developed a new way to design better antibiotics.
  • To tackle this problem, the researchers took a new approach that relied on exploiting bacterial metabolism, processes that are essential for bacteria to thrive.

A new avenue for fighting drug-resistant bacteria

Retrieved on: 
Thursday, July 15, 2021
Branches of biology, Health sciences, Biology, Bacteriology, Bacterial diseases, RNA, Microbiology, Infectious diseases, Antimicrobial resistance, Antibiotic, Bacteria, RNA interference

Professor Charles Dozois from Institut national de la recherche scientifique (INRS) and doctoral student Hicham Bessaiah see a promising avenue for more effective treatment of antibiotic-resistant bacteria.

Key Points: 
  • Professor Charles Dozois from Institut national de la recherche scientifique (INRS) and doctoral student Hicham Bessaiah see a promising avenue for more effective treatment of antibiotic-resistant bacteria.
  • The bacteria have to withstand the environmental stressors in order to cause a bladder infection.
  • "Without the regulatory RNA, the bacteria is more sensitive to changes in the environment and loses its infectious capacity," explained the doctoral student.
  • The regulatory RNA sequence studied by the researchers is also found in a number of other major pathogenic bacteria.

Accelerate Diagnostics Launches a Fast Antimicrobial Susceptibility Test for Use with Existing ID Systems in the United States

Retrieved on: 
Wednesday, July 7, 2021
Articles, IVD, Antimicrobial resistance, Life sciences

TUCSON, Ariz., July 7, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) today announced the launch of a new IVD configuration of its Accelerate PhenoTest BC kit in the United States.

Key Points: 
  • TUCSON, Ariz., July 7, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) today announced the launch of a new IVD configuration of its Accelerate PhenoTest BC kit in the United States.
  • "This product expansion provides new options for customers to access the proven benefits of our fast susceptibility testing," said Jack Phillips, Chief Executive Officer of Accelerate Diagnostics.
  • Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis.
  • The "ACCELERATE DIAGNOSTICS" and "ACCELERATE PHENO" and "ACCELERATE PHENOTEST" and diamond shaped logos and marks are trademarks or registered trademarks of Accelerate Diagnostics, Inc.
    For more information about the company, its products and technology, or recent publications, visit axdx.com .

New Accelerate Pheno® Landmark Study Validates Important Clinical Benefits to Be Presented at ECCMID 2021

Retrieved on: 
Wednesday, June 30, 2021
Health sciences, Articles, Health, Bacterial diseases, Evolutionary biology, Pharmaceuticals policy, Veterinary medicine, Antimicrobial resistance, Bloodstream infections, Infection, Antimicrobial

The purpose of this landmark study is to compare data before and after implementation of the Accelerate Pheno system across several hospitals to determine the effects of the system on treating patients with bloodstream infections.

Key Points: 
  • The purpose of this landmark study is to compare data before and after implementation of the Accelerate Pheno system across several hospitals to determine the effects of the system on treating patients with bloodstream infections.
  • The ePoster presentations are from real-world clinical use of the Accelerate Pheno system in diverse health systems and include endpoints for microbiology test turnaround time, antimicrobial use, and a subgroup analysis that measured 30-day mortality.
  • Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis.
  • Such forward looking statements include any implication that the results of the new landmark study will be realized at other customers using the Accelerate Pheno system.

Venatorx Pharmaceuticals Names Mary Beth Dorr, Ph.D. Vice President, Clinical Science

Retrieved on: 
Tuesday, June 29, 2021
Research, Human resources, Infectious diseases, Clinical trials, Professional services, Biotechnology, Health, Pharmaceutical, Science, Articles, Life sciences, Health sciences, Antiviral drug, Biocides, Antimicrobial resistance, Infection, ViroPharma, Rudi Pauwels

Venatorx Pharmaceuticals today announced that Mary Beth Dorr, Ph.D. has joined the Company as Vice President, Clinical Science.

Key Points: 
  • Venatorx Pharmaceuticals today announced that Mary Beth Dorr, Ph.D. has joined the Company as Vice President, Clinical Science.
  • Founded in 2010, Venatorx Pharmaceuticals is a private, clinical-stage pharmaceutical company focused on improving health outcomes for patients with multi-drug-resistant bacterial infections and hard-to-treat viral infections.
  • In addition, Venatorx is in Phase 1 with its first antiviral compound (VNRX-9945), a Hepatitis B virus inhibitor.
  • For more information about Venatorx, its partners, investors and pipeline development, please visit www.venatorx.com .